Duval/CIBMTR Score for AML Survival
Estimates post–allogeneic transplant survival in AML using five adverse pre‑transplant clinical risk factors.
Indications for Use
Used for adults with AML undergoing allogeneic HCT in relapse or primary induction failure to estimate post‑transplant overall survival based on five adverse pre‑HCT factors (CR1 duration <6 months, circulating blasts, non–HLA‑identical sibling donor, Karnofsky <90, adverse cytogenetics) derived from a large CIBMTR registry study. Predicts 3‑year OS ranging from 42% (score 0) to 6% (score ≥3) 1 [Level II evidence].
Insights & Cautions
Stratifies relapse/PIF AML before allo‑HCT using five adverse factors (CR1 <6 mo, circulating blasts, non‑sibling donor, Karnofsky <90, adverse cytogenetics). Three‑year OS declines from 42% (score 0) to 6% (≥3) 1 [Level II evidence].
Cautions: underestimates molecular risk (e.g., TP53, MK), was built in retrospective cohorts, and performance is lower in modern transplant platforms; use only as broad prognostic guidance, not for individual prediction.